MedTrace Logo

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

NCT07224347 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 19114

Last updated 2025-11-04

No results posted yet for this study

Summary

ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with scheduled visits and phone calls. An observational follow-up phase (ASPREE-XT), began in January, 2018. This will enable the monitoring of possible delayed effects of aspirin treatment, primarily on cancer incidence, metastases and mortality. In addition to monitoring the incidence of malignancy within the ASPREE cohort, the opportunity will be taken to observe any other residual effects of aspirin on the endpoints being monitored in the cohort. Continuity of contact with study participants is the key to retention of the cohort for any ongoing or future studies.

Conditions

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Bayer

    collaborator INDUSTRY

  • Monash University

    collaborator OTHER

  • Berman Center for Outcomes and Clinical Research

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • Anne Murray

    lead OTHER

Principal Investigators

  • Anne Murray, MD, MSc · Berman Center for Outcomes and Clinical Research

  • John McNeil, MBBS, PHD · Monash University

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-15
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07224347 on ClinicalTrials.gov